Hyaluronan-IN-1

Hyaluronan-IN-1 (Pep-1) 是一种 Kd 值为 1.65 μM 的 Hyaluronan 抑制剂,可阻断 CD44 依赖性细胞黏附并抑制细胞向透明质酸底物的黏附,通过阻断炎症细胞向皮肤的归巢过程抑制小鼠接触性超敏反应的发生,还能抑制致敏阶段的反应,减少黑色素瘤肺转移并延长小鼠生存期,可用于接触性超敏反应、慢性皮肤炎症及黑色素瘤的相关研究。
产品编号: MS-T77924 纯度: 99.84% CAS No.: 299157-43-0 分子式: C64H94N20O16 分子量: 1399.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Hyaluronan-IN-1 (Pep-1) 是一种 Kd 值为 1.65 μM 的 Hyaluronan 抑制剂,可阻断 CD44 依赖性细胞黏附并抑制细胞向透明质酸底物的黏附,通过阻断炎症细胞向皮肤的归巢过程抑制小鼠接触性超敏反应的发生,还能抑制致敏阶段的反应,减少黑色素瘤肺转移并延长小鼠生存期,可用于接触性超敏反应、慢性皮肤炎症及黑色素瘤的相关研究。

生物实验数据

生物活性 Hyaluronan-IN-1 (Pep-1) is a Hyaluronan inhibitor with a Kd value of 1.65 μM that blocks CD44-dependent cell adhesion and inhibits cell adhesion to hyaluronan substrates, suppresses the development of contact hypersensitivity in mice by blocking the homing of inflammatory cells to the skin, also inhibits the sensitization phase, reduces melanoma lung metastasis and prolongs mouse survival, and can be used for research on contact hypersensitivity, chronic skin inflammation, and melanoma.
体外研究
(In Vitro)

Hyaluronan-IN-1 (125 μg/mL; 72 h) 不会直接影响野生型 (WT) C57BL/6 小鼠小肠类器官的增殖或增殖标记基因的表达。
Hyaluronan-IN-1 (125I 标记的肽; 50 μg/mL; 1 h) 可通过 HA 包被的顺磁珠结合试验以剂量依赖方式特异性结合固定化 HA,其表观亲和常数 Kd 为 1.65 μM。
Hyaluronan-IN-1 (0-500 μg/mL; 2 h) 以剂量依赖方式抑制可溶性 HA 与 BW5147 胸腺瘤细胞的结合,在 500 μg/mL 浓度下可观察到约 75% 的抑制率。
Hyaluronan-IN-1 (500 μg/mL; 1 h) 可强效抑制 B16-F10 黑色素瘤细胞依赖 CD44 的、与 HA 包被底物的黏附作用。
Hyaluronan-IN-1 (500 μg/mL; 1 h) 可强效抑制 RPMI 7591 黑色素瘤细胞与 HA 包被底物的黏附。
Hyaluronan-IN-1 (500 μg/mL; 1 h) 可强效抑制 B16-BL6 黑色素瘤细胞黏附于 HA 包被的底物。
Hyaluronan-IN-1 (0-250 μg/mL; 24 h) 不会改变体外 B16-F10 黑色素瘤细胞的增殖。

Cell Proliferation Assay

Cell Line: WT C57BL/6 mouse small intestinal enteroids
Concentration: 125 μg/mL
Incubation Time: 72 h
Result: Showed no effect on enteroid growth measured by MTT incorporation in either stem cell-supporting or differentiation-supporting conditions.
Showed no effect on the mRNA expression of proliferation markers Ki-67 or Cyclin-D1, with no significant differences compared to control enteroids.

Cell Proliferation Assay

Cell Line: B16-F10 melanoma cells
Concentration: 0-250 μg/mL
Incubation Time: 24 h
Result: Had no effect on [3H]thymidine uptake at any tested concentration, indicating no impact on in vitro cell proliferation.
体内研究
(In Vivo)

Hyaluronan-IN-1 (40 mg/kg;腹腔注射;每周 2 次;持续 5 周) 会抑制野生型及 CD44-/- 小鼠断奶后的正常肠道与结肠生长,降低上皮细胞增殖水平并减轻体重,但对 TLR4-/- 小鼠无上述作用,表明该效应依赖于 TLR4 信号通路。
Hyaluronan-IN-1 (40 mg/kg;腹腔注射;每隔 1 天给 1 次;共 7 天) 可减少野生型及 CD44-/- 新生小鼠的隐窝裂变,抑制 Lgr5+ 干细胞增殖,抑制隐窝基底上皮细胞增殖,促进细胞凋亡并减少潘氏细胞数量,但对 TLR4-/- 小鼠无上述作用,表明这些新生小鼠肠道发育相关作用依赖于 TLR4 信号通路。
Hyaluronan-IN-1 (每耳 13.3-40 µg;皮下注射;单次或两次;DNFB 暴露前 1-3 天) 可呈剂量和时间依赖性地抑制半抗原诱导的小鼠表皮朗格汉斯细胞迁移,在 DNFB 暴露前 24 h 和 1 h 分别给予每耳 40 µg 的两次注射可实现完全抑制。
Hyaluronan-IN-1 (每耳每次注射 40 µg;皮下注射;共注射 2 次;致敏前 24 h 和 1 h 给药) 可在局部和时间上抑制小鼠接触性超敏反应的致敏阶段,且不会诱导长期无反应性。
Hyaluronan-IN-1 (每耳 40 µg-每只动物 1 mg;皮下注射、静脉注射、局部;单次或两次注射;激发前 1-24 h) 可抑制小鼠急性接触性超敏反应的诱导阶段,减轻耳肿胀、水肿及白细胞浸润。
Hyaluronan-IN-1 (每耳每次注射 40 µg;于第 0、1、3、5 天给) 可显著抑制由半抗原反复涂抹诱导的小鼠慢性皮炎。
Hyaluronan-IN-1 (每只小鼠 500 μg;静脉注射;单次联合注射) 可显著降低雌性 C57BL/6 小鼠中 B16-F10 黑色素瘤的肺转移发生率并延长生存期,肿瘤接种后 48 天的存活率为 35.1%。

Animal Model: C57BL/6J (male, wild-type, CD44-/-, TLR4-/-, 3 weeks old at study start)
Dosage: 40 mg/kg
Administration: i.p.; twice a week; 5 weeks
Result: Reduced small intestinal length, reduced colonic length, decreased jejunal villus height, decreased jejunal crypt depth, decreased colonic crypt depth, reduced number of BrdU-positive epithelial cells per proximal jejunum crypt section, reduced number of BrdU-positive epithelial cells per distal colon crypt section, and lowered average body weight by 10% compared to controls in wild-type mice.
Reduced small intestinal length, reduced colonic length, decreased jejunal villus height, decreased jejunal crypt depth, decreased colonic crypt depth, reduced number of BrdU-positive epithelial cells per proximal jejunum crypt section, reduced number of BrdU-positive epithelial cells per distal colon crypt section, and lowered average body weight by 8% compared to controls in CD44-/- mice.
Showed no significant effects on small intestinal length, colonic length, villus height, crypt depth, BrdU-positive cell counts, or body weight compared to controls in TLR4-/- mice.
Animal Model: Lgr5/EGFP C57BL/6J (wild-type, CD44-/-, TLR4-/-, 7 days old at study start)
Dosage: 40 mg/kg
Administration: i.p.; every other day; 7 days
Result: Reduced small intestinal crypt fission frequency, reduced colonic crypt fission frequency, decreased percentage of Lgr5+/BrdU+ epithelial cells in nonfissioning crypts, reduced positional epithelial proliferation at crypt base positions 1-4, increased positional apoptosis at crypt positions 1-7, and reduced Paneth cell number per crypt section in wild-type mice.
Reduced small intestinal crypt fission frequency, reduced colonic crypt fission frequency, decreased percentage of Lgr5+/BrdU+ epithelial cells in nonfissioning crypts, reduced positional epithelial proliferation at crypt base positions 1-4, showed no significant effect on apoptosis, and showed no significant effect on Paneth cell number in CD44-/- mice.
Showed no significant effects on crypt fission frequency, Lgr5+ stem cell proliferation, positional epithelial proliferation, apoptosis, or Paneth cell number compared to controls in TLR4-/- mice.
Animal Model: BALB/c (female, 6-8 weeks old)
Dosage: 40 µg/ear/injection (complete inhibition); 13.3 µg/ear (partial inhibition); 40 µg/ear (single injection, complete inhibition at 1-2 days pre-DNFB, no inhibition at 3 days pre-DNFB)
Administration: s.c.; two injections at 24 h and 1 h before DNFB application; single injection at 24 h, 1 day, 2 days, or 3 days before DNFB application
Result: Prevented DNFB-triggered Langerhans cell migration almost completely (≥80% inhibition across seven independent experiments) with two 40 µg/ear/injection doses.
Caused partial inhibition of DNFB-triggered Langerhans cell migration with a single 13.3 µg/ear dose.
Caused more prominent inhibition of DNFB-triggered Langerhans cell migration with a single 40 µg/ear dose.
Blocked DNFB-triggered Langerhans cell migration completely with a single 40 µg/ear dose administered 1 or 2 days before DNFB application.
Lost inhibitory activity for DNFB-triggered Langerhans cell migration with a single 40 µg/ear dose administered 3 days before DNFB application.
Showed equivalent inhibitory activity to its His→Ala mutant.
Abrogated inhibitory activity in its Trp→Ala mutant form.
Did not affect Langerhans cell densities in the absence of DNFB.
Animal Model: BALB/c (female, 6-8 weeks old)
Dosage: 40 µg/ear/injection
Administration: s.c.; two injections at 24 h and 1 h before sensitization
Result: Significantly reduced ear swelling responses to DNFB when sensitized with DNFB on the peptide-injected left ear.
Showed comparable ear swelling responses to OX (sensitized on the abdomen) relative to control peptide-treated mice.
Significantly reduced swelling responses to OX when sensitized with OX on the left ear.
Showed comparable swelling responses to DNFB (sensitized on the abdomen) relative to control peptide-treated mice.
Showed similar swelling responses to control peptide-treated mice when resensitized and rechallenged with DNFB, indicating no long-term unresponsiveness.
Animal Model: BALB/c (female, 6-8 weeks old)
Dosage: 40 µg/ear/injection (s.c.); 1 mg/animal (i.v.); 40 µg/ear (topical)
Administration: s.c.; two injections at 24 h and 1 h before challenge; i.v.; single injection 1 h before challenge; topical; single application 1 h before challenge after acetone skin barrier disruption
Result: Caused a significant reduction in ear swelling compared to PBS, control peptide, or Pep-2-treated mice via subcutaneous administration.
Caused significant reductions in ear swelling relative to control peptide-treated mice via intravenous and topical administration.
Reduced skin edema and leukocyte infiltration compared to controls, with statistically significant decreases in measured ear thickness and infiltrating leukocyte counts.
Animal Model: BALB/c (female, 6-8 weeks old)
Dosage: 40 µg/ear/injection
Administration: s.c.; injections on days 0, 1, 3, and 5
Result: Significantly reduced ear swelling at every time point tested compared to control peptide-treated mice, with progressive suppression of the chronic inflammatory response.
Animal Model: C57BL/6 (female, 6-8 weeks old)
Dosage: 500 μg/mouse (co-injection); 40 μg/mouse (days 3 and 6 post-inoculation)
Administration: s.c.; single co-injection; two additional injections on days 3 and 6
Result: Had no significant effect on local tumor growth at the inoculation sites, with tumor size measurements comparable to control groups.
Animal Model: C57BL/6 (female, 6-8 weeks old)
Dosage: 500 μg/mouse
Administration: i.v.; single co-injection
Result: Reduced the number of lung metastatic lesions with statistical significance (P < 0.05) compared to control groups.
Prolonged survival significantly (P < 0.01), with a median survival time of 32 days, compared to 26 days for the control peptide group and 25 days for the PBS group.
Achieved a 35.1% survival rate (13 of 37 mice) at 48 days post-inoculation, while all PBS-treated mice died by day 28 and only 2 of 30 control peptide-treated mice survived.
Resulted in no macroscopically discernible lung metastatic lesions in surviving mice.
性状 固体
颜色 White to off-white

化学信息

分子量 1399.56
分子式 C64H94N20O16
CAS No. 299157-43-0

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础